Dermata Therapeutics, Inc. (DRMA) stock

DRMANasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/30

$0.62−0.04 (-6.01%)

Close on Nov 13, 2026Market cap $2.50MP/E –Yield –

Dermata Therapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Dermata Therapeutics's ebitda for the twelve months ending Dec 31, 2021 was -$7.86M. For fiscal 2021 it was -$7.86M.

Period	Period end	Value	Change
FY2021	Dec 31, 2021	-$7.86M	–
FY2020	Dec 31, 2020	-$3.17M	–

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q1 FY2022	Mar 31, 2022	-$2.79M	–
Q4 FY2021	Dec 31, 2021	-$2.55M	–
Q3 FY2021	Sep 30, 2021	-$1.71M	–

See a number that looks wrong?